Imunon, Inc. (IMNN) Balance Sheet

NASDAQ: IMNNAssets, liabilities, debt and equity over 10 years.

IMNN balance sheet, 2025

December 31, 2025 · U.S. dollars

$12.3M assets = $5.2M liabilities + $7.1M equity

What it owns$12.3MCash & ST investments: $8.8M (71.5%)Cash & ST investments$8.8M · 71%Other current: $1.9M (15.8%)Other current$1.9M · 16%PP&E: $1.6M (12.7%)PP&E$1.6M · 13%=How it is financed$12.3MCurrent liabilities: $4.6M (37.6%)Current liabilities$4.6M · 38%Other LT liabilities: $602,000 (4.9%)Shareholders’ equity: $7.1M (57.5%)Shareholders’ equity$7.1M · 57%

Both columns are drawn to the same scale: what IMNN owns equals what it owes plus shareholders’ equity. Hover a block for its value.

IMNN financial health

Current ratio2.32
Comfortable · current assets cover current liabilities 2.32×
Debt / equity0.14
Low leverage · $0.14 of debt for each $1 of equity
Equity / assets57.5%
Equity-funded · of assets funded by shareholders
Cash / debt871.1%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

IMNN balance sheet trends, 2016–2025

Imunon, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$30.8M2016$12.3M2025−9.7%/yr
Total liabilities$24.1M2016$5.2M2025−15.6%/yr
Shareholders’ equity$6.7M2016$7.1M2025+0.5%/yr
Cash & short-term investments$4.3M2016$8.8M2025+8.2%/yr
Total debt$2.6M2016$1.0M2025−9.8%/yr
Net cash (debt)$1.7M2016$7.8M2025+$6.0M
Working capital−$3.9M2016$6.1M2025+$10.0M
Current ratio0.5420162.322025+1.78
Debt / equity0.3820160.142025−0.24

Change is the average annual growth (CAGR) or the difference between the first and latest year.

IMNN assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

IMNN liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

IMNN debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

IMNN balance sheet

Imunon, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$8.8M$5.9M$15.7M$32.7M$49.4M$17.2M$14.9M$27.6M$24.2M$4.3M
Cash & equivalents$8.8M$5.9M$5.8M$11.5M$19.6M$17.2M$6.9M$13.4M$11.4M$2.6M
Short-term investments—$0$9.9M$21.3M$29.8M$0$8.0M$14.3M$12.7M$1.7M
Receivables$0$0$0$128,932$108,844$0$21,369$68,309$54,440$4,008
Inventory$0$0$0$1.4M$2.3M$0$0$0$0$84,770
Other current assets$1.9M$2.1M$2.5M$2.5M$109,257$1.7M$1.4M$451,293$89,186$119,638
Total current assets$10.7M$8.0M$18.2M$36.8M$51.9M$18.8M$16.2M$28.1M$24.3M$4.5M
Property, plant & equipment (net)$1.6M$1.7M$2.3M$704,177$1.2M$1.3M$1.8M$184,627$175,771$462,836
Goodwill & intangible assets$0$0$0$0$13.4M$15.5M$18.1M$18.3M$23.0M$25.8M
Long-term investments$0$0$0$0$0$0$0$0$0$0
Other non-current assets$0$50,000$1.3M$6.5M$7.6M$1.9M$2.2M$258,933$8,761$108,761
Total assets$12.3M$9.7M$21.9M$44.0M$74.0M$37.5M$38.3M$46.9M$47.5M$30.8M
Liabilities
Accounts payable$1.4M$1.3M$3.5M$3.6M$2.5M$2.2M$2.9M$3.0M$3.4M$2.9M
Short-term debt$406,354$452,358$485,421$1.7M$548,870$1.6M$2.2M——$2.6M
Deferred revenue———−$4.8M$500,000$500,000$500,000$500,000$500,000$500,000
Total current liabilities$4.6M$4.8M$7.4M$10.0M$6.8M$6.8M$7.9M$6.1M$6.2M$8.4M
Long-term debt$0$0$0$4.6M$5.9M$3.9M$8.0M$9.4M$0$0
Lease obligations$1.0M$1.1M$1.6M$231,000$779,619$1.1M$1.5M———
Other long-term liabilities$602,000$686,935$1.1M$0$5.6M$8.2M$7.9M$10.5M$14.6M$15.7M
Total liabilities$5.2M$5.5M$8.5M$14.6M$18.3M$18.9M$23.7M$26.0M$20.8M$24.1M
Shareholders' equity
Common stock & paid-in capital$34,000$145,007$93,998$74,362$57,705$27,134$232,562$188,322$172,772$22,305
Retained earnings (deficit)−$421.3M−$406.8M−$388.2M−$368.7M−$332.8M−$312.0M−$290.5M−$273.7M−$261.8M−$241.4M
Accumulated other comprehensive income——$60,796$26,494−$7,974$0$42,778$29,872−$10,164$0
Total shareholders' equity$7.1M$4.2M$13.4M$29.3M$55.8M$18.6M$14.6M$20.9M$26.7M$6.7M
Key figures
Total debt$1.0M$1.1M$1.6M$6.3M$6.6M$6.2M$11.3M$9.4M—$2.6M
Net cash (debt)$7.8M$4.7M$14.1M$26.5M$42.8M$11.0M$3.5M$18.2M—$1.7M
Working capital$6.1M$3.2M$10.8M$26.7M$45.2M$12.1M$8.3M$22.0M$18.1M−$3.9M
Tangible book value$7.1M$4.2M$13.4M$29.3M$42.4M$3.2M−$3.5M$2.6M$3.7M−$19.0M
Book value per share$3.33—————————
Shares outstanding2.1M—————————
Current ratio2.321.672.473.667.672.792.064.613.920.54
Quick ratio1.901.232.123.287.312.541.894.533.910.51
Debt / equity0.140.270.120.210.120.330.780.45—0.38
Equity / assets57.5%43.7%61.1%66.7%75.4%49.6%38.0%44.5%56.2%21.8%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 31, 2026); data from EODHD.

IMNN financial position

At the end of fiscal 2025 (December 31, 2025), Imunon had total assets of $12.3 million (up 26.5% from a year earlier), total liabilities of $5.2 million and shareholders' equity of $7.1 million. It held $8.8 million in cash and short-term investments against $1.0 million of debt, a net cash position of $7.8 million. Its current ratio was 2.32. In the latest quarter (ended June 30, 2026) total assets were $15.0 million and equity $4.2 million.

Related: IMNN income statement, IMNN cash flow statement, IMNN key metrics. See the IMNN stock overview for the latest quote and news.

IMNN balance sheet FAQ

What are Imunon's total assets?

Imunon reported total assets of $12.3 million at the end of fiscal 2025 (December 31, 2025), compared with $9.7 million a year earlier.

How much debt does Imunon have?

Imunon had $1.0 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.14.

How much cash does Imunon have?

Imunon held $8.8 million in cash and short-term investments at the end of fiscal 2025; with $1.0 million of debt that is net cash of $7.8 million.

What is Imunon's book value?

Imunon's shareholders' equity (book value) was $7.1 million at the end of fiscal 2025, or $3.33 per share.

What is Imunon's current ratio?

Imunon had current assets of $10.7 million and current liabilities of $4.6 million, a current ratio of 2.32 (it can cover its short-term obligations).

Biotechnology: balance sheet